CN101658502A - Metronidazole sustained-release tablets and preparation method thereof - Google Patents
Metronidazole sustained-release tablets and preparation method thereof Download PDFInfo
- Publication number
- CN101658502A CN101658502A CN200810118870A CN200810118870A CN101658502A CN 101658502 A CN101658502 A CN 101658502A CN 200810118870 A CN200810118870 A CN 200810118870A CN 200810118870 A CN200810118870 A CN 200810118870A CN 101658502 A CN101658502 A CN 101658502A
- Authority
- CN
- China
- Prior art keywords
- metronidazole
- cellulose
- slow releasing
- releasing tablet
- film coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention aims to provide metronidazole sustained-release tablets with higher stability of medicament release and administrative safety, which have the characteristics of improving curative effect, reducing side effect, difficulty generating medicament resistance, having convenient administration, improving the compliance of patients and the like. The metronidazole sustained-release tablets are characterized by consisting of metronidazole, a slow release material, a filler, a glidant, a lubricating agent, a wetting agent and a film coating material.
Description
Technical field
The present invention relates to a kind of metronidazole sustained-release tablets and preparation method thereof, belong to field of medicaments.
Background technology
Metronidazole is a kind of synthetic oral antigen worm medicine and antimicrobial drug.
Metronidazole may be brought into play antibacterial activity by following mechanism under anaerobic environment: be subjected to ion transporter effect in the cell after medicine enters body, form a kind of Concentraton gradient that impels medicine to intracellular transport.Medicine forms free radical in cell, working with cellular content conversely finally causes microbial death.
Gynecological inflammation is meant that female genital system meets with the caused disease of viral infection.World Health Organization (WHO) shows Chinese women's investigation: China adult female population statistics is about 1.5～200,000,000, and wherein about 41% women suffers from gynecological's inflammatory diseases in various degree, and married women's sickness rate is more up to 70%.
" the Chinese Amino-Cerv market analysis report " of one Xinda, east says that gynecological inflammation medication market scale was about 56.8 hundred million yuan in 2006, than increasing by 15.56% last year; Gynecological inflammation medication market will increase by 11.70% than 2006 in 2007, and market scale will reach 63.45 hundred million yuan; Gynecological inflammation medication market scale will be up to 77.55 hundred million yuan in 2008.
Metronidazole is to the powerful antibacterial action of most of anaerobe tools, but aerobe and facultative anaerobe are not had effect.Antimicrobial spectrum comprises bacteroides fragilis and other Bacteroidess, fusiform bacilarmature, aerogenesis clostruidium, Eubacterium, Wei Rong coccus, dyspepsiacoccus and peptostreptococcus etc.Actinomyces, Lactobacillus, propionibacterium are to this product drug resistance.The a little higher than Mlc of its bacteriocidal concentration.The sterilization mechanism of this product is not illustrated as yet fully, and the nitroreductase of anaerobe plays an important role in the energy metabolism of sensitive strain.The nitro of this product is reduced into a kind of cell toxicant, thereby acts on the DNA metabolic process of cell, impels antibacterial death.Fastbacteria often lacks nitroreductase and to this product drug resistance.The mechanism of the anti-ameba of this product ruptures the protozoacide nitrogen chain, thereby kills protozoon for suppressing its redox reaction.
Metronidazole of many uses all has tangible curative effect at multiple pathogenic bacteria property disease:
(1), treatment peptic ulcer.Metronidazole treatment peptic ulcer is effective, and gastric epithelial cell and secretory function thereof are improved, and strengthens the sticking barrier and the mucus barrier touched of stomach.
(2), treatment respiratory system disease.Treat acute episode of chronic bronchitis with metronidazole, empyema.
(3), treatment hyperlipemia.Metronidazole treatment hyperlipemia is rapid-action, short treating period, and side effect is little.Can be considered the blood lipid-lowering medicine of quick-acting, produce effects, safety.
(4), treatment oral cavity department disease.Treat chronic gingivitis, simple property gingival hemorrhage, acute and chronic periapical periodontitis, periodontal disease with metronidazole, metronidazole has become a kind of newtype drug of the department of stomatology.
(5), treatment gynaecopathia.Be used for the multiple vaginitis of clinical treatment, acute pelvic inflammatory disease.Metronidazole is the ideal medicament of treatment gynecological infection.
(6), treatment cutaneous diseases.With metronidazole external preparation treatment folliculitis, acne and seborrheic dermatitis, scabies, rosacea, psoriasis, tinea pedis, papular urticaria.Metronidazole all has good effect to the various skin disease, may be relevant with its parasite killing, antiallergic and anaerobe resistant effect.
(7), control anaerobic infection disease.Because metronidazole has stronger anaerobe resistant effect, can be used for treating infectious disease due to each system's anaerobe as septicemia, endocarditis, lower respiratory infection, intra-abdominal infection, central nervous system, osteoarthrosis and skin soft-tissue infection and maxillary sinusitis, liver abscess, cholecystitis, chronic colitis and chronic prostatitis etc.Metronidazole prevents the appendicitis postoperative wound to infect in addition simultaneously.Reduce the generation of bone wound postoperative infection.The effect of remarkable prevention of postoperative abdominal adhesions is arranged.
Generally speaking, metronidazole is widely used as a kind of antibacterials, and curative effect is obvious, is a kind of antibiotic that the market advantage is arranged.China manufacturer reaches over one hundred family, but focus disperses leader's property brand that shortage is all had outstanding performance on academic and market.
The metronidazole sustained-release tablets of the present invention's preparation changes the drug release form, has improved curative effect, has reduced side effect, has been difficult for producing drug resistance and taking convenience.Therefore, in the competition of similar medicine, form certain advantage surely.
Beneficial effect
1, compare with conventional formulation, the slow releasing preparation rate of releasing drug is steady, near the zero level rate process, can overcome " peak valley " phenomenon that is produced behind the ordinary preparation multiple dose administration.After conventional formulation was taken medicine, drug level rose to maximum rapidly, because metabolism is drained and Degradation, reduced rapidly again then, drug level was controlled between minimum effective drug concentration and the maximum safe concentration relatively more difficult;
2, can make in the body effective blood drug concentration length of holding time, and steadily, utilization ratio of drug can reach 80～90%, and the utilization rate of conventional medicine only is 40～60%;
3, can reduce medicine to the gastrointestinal side effect.Conventional formulation is made controlled release preparation and can be reduced side effect because the disintegrate stripping rapidly in intestinal of oral back is big to GI irritation;
4, comparing general formulation makes its curative effect raising, side effect reduce, be difficult for producing drug resistance, taking convenience, having improved patient's compliance.
Summary of the invention
The purpose of this invention is to provide a kind of stability of medicine release and the higher metronidazole sustained-release tablets of safety of medication, have and improve curative effect, reduce side effect, be difficult for producing drug resistance, taking convenience, improved characteristics such as patient's compliance.
Metronidazole sustained-release tablets of the present invention is characterized in that being made up of metronidazole, slow-release material, filler, fluidizer, lubricant, wetting agent, thin film coating material.
Slow releasing tablet of the present invention, the metronidazole effective dose is 100mg～2000mg, is preferably 300mg～1000mg.
Slow releasing tablet of the present invention, it is characterized in that described slow-release material is selected from one or more in hydroxypropyl methylcellulose, Sulisi aqueous dispersion, ethyl cellulose, methylcellulose, cellulose acetate-phthalate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, cellulose acetate, cellulose diacetate, Triafol T, glyceryl monostearate, the hydroxy methocel, preferred hydroxypropyl methylcellulose.
Slow releasing tablet of the present invention, it is characterized in that described filler is selected from one or more in microcrystalline Cellulose, mannitol, copolyvidone, polyvidone, low-substituted hydroxypropyl cellulose, polyvinyl alcohol, poly-phthalic acid vinyl acetate, Polyethylene Glycol, sodium alginate, chitosan, sucrose, lactose, starch, dextrin, Icing Sugar, cross linked polyvinyl pyrrolidone, cross-linking sodium carboxymethyl cellulose, pregelatinized Starch, the titanium dioxide, preferably microcrystalline cellulose, copolyvidone.
Slow releasing tablet of the present invention is characterized in that described fluidizer is selected from micropowder silica gel, Pulvis Talci, Cab-O-sil, Arosil, hydrated sodium aluminosilicate, preferred micropowder silica gel.
Slow releasing tablet of the present invention is characterized in that described lubricant is selected from one or more in magnesium stearate, micropowder silica gel, Pulvis Talci, hydrogenated vegetable oil, polyethylene glycols, month pure magnesium sulfate of extension, preferred magnesium stearate.
Slow releasing tablet of the present invention, it is characterized in that described wetting agent is selected from kind in water, methanol, ethanol, dehydrated alcohol, starch slurry, chloroform, acetone, polyvidone, crospolyvinylpyrrolidone, hydroxypropyl methylcellulose and/or other cellulose families or more than one, preferred water.
Slow releasing tablet of the present invention, it is characterized in that described thin film coating material is selected from one or more in ethyl cellulose, starch, Aquacoat, methylcellulose, cellulose acetate, acrylic resin, Opadry, the Sulisi, preferred Opadry.
Slow releasing tablet of the present invention is characterized in that counting by weight percentage, and it consists of:
Slow-release material 0～30%
Filler 0～20%
Wetting agent is an amount of
Thin film coating material 0～10%
The preparation method of slow releasing tablet of the present invention, it comprises following steps:
(1) plain sheet preparation technology
(1.1) granulate
Get metronidazole, the fluidizer mixing of recipe quantity, be crushed to and can cross 80 orders, standby.Metronidazole, fluidizer mixture after getting slow-release material, the filler of recipe quantity and crossing 80 mesh sieves together packed in the wet mixing pelletizer, stirring makes mix homogeneously, use atomizing type to spray into an amount of wetting agent to granulator behind the mixing, continue to stir and make into granule, take out granule and cross the 16 mesh sieves granulate that wets, granule is in aeration-drying below 55 ℃; Dried particles is carried out moisture content detects, detect qualified after, reuse 16 mesh sieves carry out granulate, and are standby.
(1.2) tabletting
The mix lubricant of the granule that makes and recipe quantity is even, and detection level determines that sheet is heavy, and with the stamping of φ 20 * 9mm scrobicula, Hardness Control is in 9～11kg scope.
(2) film coating procedure
(2.1) preparation of coating solution
The thin film coating material of recipe quantity is added in the prescription water gaging, stirred 45 minutes, make whole dissolvings dispersions, be mixed with Opadry concentration and be 5～30% homogeneous aqueous dispersion, standby.
(2.2) film coating
The plain sheet that makes is put in the high-efficiency coating machine, and inlet temperature is heated to about 50～60 ℃, at the uniform velocity sprays into coating solution and carries out coating, and the sheet bed tempertaure remains on 40～45 ℃, and it is about 3% that coating increases weight, promptly.
Slow releasing tablet of the present invention, it is characterized in that described slow releasing tablet is according to drug release determination method (two appendix XD of Chinese Pharmacopoeia version in 2005), adopt dissolution method (two XC of Chinese Pharmacopoeia version in 2005) first subtraction unit, 900ml is a solvent with phosphate buffer (PH6.8), rotating speed is that per minute 100 changes, operation in accordance with the law, 1,3,6, getting solution 10ml in 12 hours respectively filters, and in process container, replenish above-mentioned solvent 10ml immediately, precision is measured each 1ml of subsequent filtrate respectively, become the solution that contains metronidazole 10 μ g among every 1ml approximately with above-mentioned solvent dilution, according to ultraviolet visible spectrophotometry (two appendix IV of Chinese Pharmacopoeia version in 2005 A), measure absorbance respectively at the wavelength place of 319nm; It is an amount of that precision takes by weighing the metronidazole reference substance in addition, adds the also quantitative dilution of above-mentioned dissolution with solvents and make the solvent that contains metronidazole 10 μ g among every 1ml approximately, measures with method, calculates every burst size at different time respectively.The slow releasing tablet of the present invention preparation should should be the 10-25% of labelled amount 1,3,6 respectively mutually with 12 hours burst size, and 25-50% is more than the 50-75% and 75%.
Specific embodiment
Embodiment 1
Prescription:
Metronidazole 750g
Hydroxypropyl emthylcellulose (K4M) 67g
Hypromellose E5 67g
Copolyvidone S-630 50g
Microcrystalline Cellulose 101 50g
Micropowder silica gel 3.8g
Magnesium stearate 4g
Water is an amount of
Make 1000 altogether
Thin film coating material
Opadry 24.8g
Water 182g
Preparation technology
1. plain sheet preparation technology
1.1 granulate
Get metronidazole, the micropowder silica gel mixing of recipe quantity, be crushed to and can cross 80 orders, standby.Metronidazole, micropowder silica gel mixture after getting hypromellose (K4M), hypromellose (E5), copolyvidone S-630, the microcrystalline Cellulose 101 of recipe quantity and crossing 80 mesh sieves together packed in the wet mixing pelletizer, stirring makes mix homogeneously, use atomizing type to spray into an amount of wetting agent water to granulator behind the mixing, continue to stir and make into granule, take out granule and cross the 16 mesh sieves granulate that wets, granule is in aeration-drying below 50 ℃; Dried particles is carried out moisture content detect, detect qualified (granule moisture content 2.0～3.0%), reuse 16 mesh sieves carry out granulate, and are standby.
1.2 tabletting
With the granule that makes and the magnesium stearate mix homogeneously of recipe quantity, detection level determines that sheet is heavy, and with the stamping of φ 20 * 9mm scrobicula, Hardness Control is in 9～11kg scope.
2 art for coating
2.1 the preparation of coating solution
The Opadry of recipe quantity is added in the prescription water gaging, stirred 45 minutes, make whole dissolvings dispersions, be mixed with Opadry concentration and be 12% homogeneous aqueous dispersion, standby.
2.2 coating
The plain sheet that makes is put in the high-efficiency coating machine, and inlet temperature is heated to about 50～60 ℃, at the uniform velocity sprays into coating solution and carries out coating, and the sheet bed tempertaure remains on 40～45 ℃, and it is about 3% that coating increases weight, promptly.
Embodiment 2
Prescription:
Metronidazole 750g
Hydroxypropyl emthylcellulose (K4M) 65g
Hypromellose E5 60g
Copolyvidone S-630 50g
Microcrystalline Cellulose 101 50g
Micropowder silica gel 3.8g
Magnesium stearate 10g
Water is an amount of
Make 1000 altogether
Thin film coating material
Opadry 30g
Water 182.3g
Preparation technology
1. plain sheet preparation technology
1.1 granulate
Get metronidazole, the micropowder silica gel mixing of recipe quantity, be crushed to and can cross 80 orders, standby.Metronidazole, micropowder silica gel mixture after getting hypromellose (K4M), hypromellose (E5), copolyvidone S-630, the microcrystalline Cellulose 101 of recipe quantity and crossing 80 mesh sieves together packed in the wet mixing pelletizer, stirring makes mix homogeneously, use atomizing type to spray into an amount of wetting agent water to granulator behind the mixing, continue to stir and make into granule, take out granule and cross the 16 mesh sieves granulate that wets, granule is in aeration-drying below 55 ℃; Dried particles is carried out moisture content detect, detect qualified (granule moisture content 2.0～3.0%), reuse 16 mesh sieves carry out granulate, and are standby.
1.2 tabletting
With the granule that makes and the magnesium stearate mix homogeneously of recipe quantity, detection level determines that sheet is heavy, and with the stamping of φ 20 * 9mm scrobicula, Hardness Control is in 9～11kg scope.
2 art for coating
2.1 the preparation of coating solution
The Opadry of recipe quantity is added in the prescription water gaging, stirred 45 minutes, make whole dissolvings dispersions, be mixed with Opadry concentration and be 18% homogeneous aqueous dispersion, standby.
2.2 coating
The plain sheet that makes is put in the high-efficiency coating machine, and inlet temperature is heated to about 50～60 ℃, at the uniform velocity sprays into coating solution and carries out coating, and the sheet bed tempertaure remains on 40～45 ℃, and it is about 2% that coating increases weight, promptly.
For investigating the slow releasing tablet release in vitro effect of the present invention's preparation, according to drug release determination method (two appendix XD of Chinese Pharmacopoeia version in 2005), adopt dissolution method (two XC of Chinese Pharmacopoeia version in 2005) first subtraction unit, 900ml is a solvent with phosphate buffer (PH6.8), rotating speed is that per minute 100 changes, operation in accordance with the law, 1,3,6, getting solution 10ml in 12 hours respectively filters, and in process container, replenish above-mentioned solvent 10ml immediately, precision is measured each 1ml of subsequent filtrate respectively, become the solution that contains metronidazole 10 μ g among every 1ml approximately with above-mentioned solvent dilution, according to ultraviolet visible spectrophotometry (two appendix IV of Chinese Pharmacopoeia version in 2005 A), measure absorbance respectively at the wavelength place of 319nm; It is an amount of that precision takes by weighing the metronidazole reference substance in addition, adds the also quantitative dilution of above-mentioned dissolution with solvents and make the solvent that contains metronidazole 10 μ g among every 1ml approximately, measures with method, calculates every burst size at different time respectively.
The slow releasing tablet of the present invention preparation should should be the 10-25% of labelled amount 1,3,6 respectively mutually with 12 hours burst size, and 25-50% is more than the 50-75% and 75%.
The metronidazole sustained-release tablets of two embodiment preparations, release characteristic is:
The metronidazole sustained-release tablets releasing curve diagram of two embodiment preparations is seen accompanying drawing 1.
Claims (7)
1, a kind of metronidazole sustained-release tablets is characterized in that being made up of metronidazole, slow-release material, filler, fluidizer, lubricant, wetting agent, thin film coating material.
2, the described slow releasing tablet of claim 1, the metronidazole effective dose is 100mg～2000mg, is preferably 300mg～1000mg.
3, each described slow releasing tablet among the claim 1-2 is characterized in that:
Described slow-release material is selected from one or more in hydroxypropyl methylcellulose, Sulisi aqueous dispersion, ethyl cellulose, methylcellulose, cellulose acetate-phthalate, hydroxypropyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxyethyl-cellulose, cellulose acetate, cellulose diacetate, Triafol T, glyceryl monostearate, the hydroxy methocel, preferred hydroxypropyl methylcellulose.
Described filler is selected from one or more in microcrystalline Cellulose, mannitol, copolyvidone, polyvidone, low-substituted hydroxypropyl cellulose, polyvinyl alcohol, poly-phthalic acid vinyl acetate, Polyethylene Glycol, sodium alginate, chitosan, sucrose, lactose, starch, dextrin, Icing Sugar, cross linked polyvinyl pyrrolidone, cross-linking sodium carboxymethyl cellulose, pregelatinized Starch, the titanium dioxide, preferably microcrystalline cellulose, copolyvidone.
Described fluidizer is selected from micropowder silica gel, Pulvis Talci, Cab-O-sil, Arosil, hydrated sodium aluminosilicate, preferred micropowder silica gel.
Described lubricant is selected from one or more in magnesium stearate, micropowder silica gel, Pulvis Talci, hydrogenated vegetable oil, polyethylene glycols, month pure magnesium sulfate of extension, preferred magnesium stearate.
Described wetting agent is selected from kind in water, methanol, ethanol, dehydrated alcohol, starch slurry, chloroform, acetone, polyvidone, crospolyvinylpyrrolidone, hydroxypropyl methylcellulose and/or other cellulose families or more than one, preferred water.
Described thin film coating material is selected from one or more in ethyl cellulose, starch, Aquacoat, methylcellulose, cellulose acetate, acrylic resin, Opadry, the Sulisi, preferred Opadry.
4, aforesaid right requires the slow releasing tablet described in the 1-3, it is characterized in that counting by weight percentage, and it consists of:
Metronidazole 20～90%
Slow-release material 0～30%
Filler 0～20%
Fluidizer 0～5%
Lubricant 0～5%
Wetting agent is an amount of
Thin film coating material 0～10%
5, aforesaid right requires the slow releasing tablet described in the 1-4, it is characterized in that calculating by weight, and it consists of:
Metronidazole 750g
Hydroxypropyl emthylcellulose (K4M) 67g
Hypromellose E5 67g
Copolyvidone S-630 50g
Microcrystalline Cellulose 101 50g
Micropowder silica gel 3.8g
Magnesium stearate 4g
Water is an amount of
Make 1000 altogether
Thin film coating material
Opadry 24.8g
Water 182g
6, the preparation method of each described slow releasing tablet among the claim 1-5, it comprises following steps:
(1) plain sheet preparation technology
(1.1) granulate
Get metronidazole, the fluidizer mixing of recipe quantity, be crushed to and can cross 80 orders, standby.Metronidazole, fluidizer mixture after getting slow-release material, the filler of recipe quantity and crossing 80 mesh sieves together packed in the wet mixing pelletizer, stirring makes mix homogeneously, use atomizing type to spray into an amount of wetting agent to granulator behind the mixing, continue to stir and make into granule, take out granule and cross the 16 mesh sieves granulate that wets, granule is in aeration-drying below 55 ℃; Dried particles is carried out moisture content detects, detect qualified after, reuse 16 mesh sieves carry out granulate, and are standby.
(1.2) tabletting
The mix lubricant of the granule that makes and recipe quantity is even, and detection level determines that sheet is heavy, and with the stamping of φ 20 * 9mm scrobicula, Hardness Control is in 9～11kg scope.
(2) film coating procedure
(2.1) preparation of coating solution
The thin film coating material of recipe quantity is added in the prescription water gaging, stirred 45 minutes, make whole dissolvings dispersions, be mixed with Opadry concentration and be 5～30% homogeneous aqueous dispersion, standby.
(2.2) film coating
The plain sheet that makes is put in the high-efficiency coating machine, and inlet temperature is heated to about 50～60 ℃, at the uniform velocity sprays into coating solution and carries out coating, and the sheet bed tempertaure remains on 40～45 ℃, and it is about 3% that coating increases weight, promptly.
7, each described slow releasing tablet among the claim 1-6, it is characterized in that: described slow releasing tablet is according to drug release determination method (two appendix XD of Chinese Pharmacopoeia version in 2005), adopt dissolution method (two XC of Chinese Pharmacopoeia version in 2005) first subtraction unit, 900ml is a solvent with phosphate buffer (PH6.8), rotating speed is that per minute 100 changes, operation in accordance with the law, 1,3,6, getting solution 10ml in 12 hours respectively filters, and in process container, replenish above-mentioned solvent 10ml immediately, precision is measured each 1ml of subsequent filtrate respectively, become the solution that contains metronidazole 10 μ g among every 1ml approximately with above-mentioned solvent dilution, according to ultraviolet visible spectrophotometry (two appendix IV of Chinese Pharmacopoeia version in 2005 A), measure absorbance respectively at the wavelength place of 319nm; It is an amount of that precision takes by weighing the metronidazole reference substance in addition, adds the also quantitative dilution of above-mentioned dissolution with solvents and make the solvent that contains metronidazole 10 μ g among every 1ml approximately, measures with method, calculates every burst size at different time respectively.The slow releasing tablet of the present invention preparation should should be the 10-25% of labelled amount 1,3,6 respectively mutually with 12 hours burst size, and 25-50% is more than the 50-75% and 75%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810118870A CN101658502A (en) | 2008-08-26 | 2008-08-26 | Metronidazole sustained-release tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200810118870A CN101658502A (en) | 2008-08-26 | 2008-08-26 | Metronidazole sustained-release tablets and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101658502A true CN101658502A (en) | 2010-03-03 |
Family
ID=41786907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200810118870A Pending CN101658502A (en) | 2008-08-26 | 2008-08-26 | Metronidazole sustained-release tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101658502A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108567755A (en) * | 2018-06-25 | 2018-09-25 | 江苏鹏鹞药业有限公司 | Metronidazole tablet and preparation method thereof |
| CN110974792A (en) * | 2019-12-26 | 2020-04-10 | 南京亿华药业有限公司 | Crystalline drug tablet and preparation method thereof |
-
2008
- 2008-08-26 CN CN200810118870A patent/CN101658502A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108567755A (en) * | 2018-06-25 | 2018-09-25 | 江苏鹏鹞药业有限公司 | Metronidazole tablet and preparation method thereof |
| CN110974792A (en) * | 2019-12-26 | 2020-04-10 | 南京亿华药业有限公司 | Crystalline drug tablet and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1138320B1 (en) | Floating forms containing drug, polyvinyl acetate and polyvinyl pyrrolidone, their use and preparation | |
| CN104147041A (en) | Dispersion preparation containing colloidal bismuth pectin and preparation method thereof | |
| CN102138911B (en) | Divalproex sodium sustained release tablets and preparation method thereof | |
| CN101658501A (en) | Minocycline hydroehloride sustained- release tablets and preparation method thereof | |
| CN101406463B (en) | Metronidazole, clotrimazole and chlorhexidime vaginal effervescent tablet and preparation method | |
| CN102119931B (en) | Novel metformin hydrochloride slow-releasing tablet and preparation method thereof | |
| CN103263395A (en) | Telmisartan tablet preparation and preparation method thereof | |
| CN101658502A (en) | Metronidazole sustained-release tablets and preparation method thereof | |
| CN110917161B (en) | Metronidazole tablet and preparation method thereof | |
| CN102885793B (en) | Nifuratel compound tablet and preparation method thereof | |
| CN101278917A (en) | Method for preparing povidone iodine vaginal tablet | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN102451171B (en) | Tindazole vaginal effervescent tablet and preparation method thereof | |
| CN106580898B (en) | A kind of erigeron breviscapus dispersion tablet and preparation method | |
| CN102335148A (en) | Compound Omeprazole tablets and preparation method thereof | |
| CN101450053A (en) | Metronidazole stomatocace double-layer paster and preparation method thereof | |
| CN105919960B (en) | A kind of roxithromycin dispersing tablet and preparation method thereof | |
| CN109172614A (en) | A kind of dedicated probiotic composition of women and its application | |
| KR20190110771A (en) | Compact dispersible tablet comprising deferacirox | |
| CN103127108A (en) | Telmisartan amlodipine tablet, and preparation method and use thereof | |
| CN106420726A (en) | Clotrimazole vaginal tablets | |
| WO2013177833A1 (en) | Dysmenorrhea-treating medicament and preparation method therefor | |
| CN102600141B (en) | Dispersible tablet containing amoxicillin and potassium clavulanate | |
| CN1304002C (en) | Vaginal effervescence tablet of secnidazole and its preparation | |
| CN103385862B (en) | A kind of metoprolol tartrate extended release tablets and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100303 |